A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 With Once Weekly Dosing of Placebo and Daily Norditropin FlexPro in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Acronyms REAL 1
- Sponsors Novo Nordisk
- 28 Feb 2017 Planned End Date changed from 1 May 2018 to 7 May 2018.
- 27 Dec 2016 Planned primary completion date changed from 1 May 2018 to 1 May 2017.
- 04 Oct 2016 Status changed from recruiting to active, no longer recruiting.